18F-FDG PET/CT in evaluating non-CNS pediatric malignancies

Area of Science:

• Nuclear Medicine
• Pediatric Oncology
• Diagnostic Imaging

Background:

• Non-central nervous system (CNS) pediatric malignancies require accurate staging and monitoring.
• Conventional imaging (CI) has limitations in fully assessing tumor burden and treatment response.
• Fluorodeoxyglucose (18F) positron emission tomography/computed tomography (FDG PET/CT) is an evolving imaging technique.

Purpose of the Study:

• To evaluate the efficacy of FDG PET/CT in pediatric patients with non-CNS malignancies.
• To compare the diagnostic performance of FDG PET/CT with conventional imaging.
• To determine if FDG PET/CT provides additional information to CI.

Main Methods:

• Retrospective review of 151 FDG PET/CT examinations in 55 pediatric patients.
• Comparison of FDG PET/CT findings with concurrent CI (contrast CT or MRI) for 108 examinations.
• Analysis of diagnostic accuracy based on histopathology or long-term follow-up (>1 year).

Main Results:

• FDG PET/CT showed higher diagnostic accuracy than CI, particularly in identifying small lymph nodes missed by CI.
• FDG PET/CT provided additional diagnostic information in 34% of examinations (13% positive, 21% negative findings).
• Accurate findings were achieved in 90% of lesions with discordant results between FDG PET/CT and CI.

Conclusions:

• FDG PET/CT demonstrates superior diagnostic performance compared to CI for pediatric non-CNS malignancies.
• FDG PET/CT offers significant additional value in over one-third of patient evaluations.
• FDG PET/CT is a reliable and accurate imaging modality for this patient population.